Jpmorgan Chase & CO Cybin Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CYBN
# of Institutions
8Shares Held
66.1KCall Options Held
0Put Options Held
0-
Emfo, LLC24.5KShares$233,0020.01% of portfolio
-
Unique Wealth Strategies, LLC Burr Ridge, IL12.7KShares$120,8080.0% of portfolio
-
Victory Financial Group, LLC Austin, TX11.7KShares$111,4880.0% of portfolio
-
Covington Capital Management10KShares$95,2000.0% of portfolio
-
Kistler Tiffany Companies, LLC Berwyn, PA3.6KShares$34,2720.0% of portfolio
About CYBIN INC.
- Ticker CYBN
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 166,120,000
- Market Cap $1.58B
- Description
- Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...